[1] Galle PR, Tovoli F, Foerster F, et al.The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. J Hepatol, 2017, 67:173-183.
[2] Bolondi L, Burroughs A, Dufour JF, et al.Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis, 2012, 32:348-359.
[3] Forner A, Gilabert M, Bruix J, et al.Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol, 2014, 11:525-535.
[4] Piscaglia F, Bolondi L.The intermediate hepatocellular carcinoma stage: Should treatment be expanded? Dig Liver Dis, 2010, 42:S258-S263.
[5] Raoul JL, Sangro B, Forner A, et al.Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev, 2011, 37:212-220. |
